Impel Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-74.28	-106.31	-76.67	-46.32	-42.36
Depreciation & Amortization	2.48	2.18	1.09	1.08	0.72
Share-Based Compensation	4.74	5.19	3.13	3.64	0.79
Other Operating Activities	-12.03	5.3	5.95	1.9	3.86
Operating Cash Flow	-79.09	-93.64	-66.36	-39.18	-36.49
Capital Expenditures	-2.88	-1.38	-0.41	-1.78	-1.52
Investing Cash Flow	-2.88	-1.38	-0.41	-1.78	-1.52
Share Issuance / Repurchase	-0.07	4.46	121.11	0.88	0.02
Debt Issued / Paid	7.06	14.59	26.58	9.7	0
Other Financing Activities	-	48.42	0.2	0.48	-
Financing Cash Flow	6.99	67.46	147.89	11.06	0.02
Net Cash Flow	-74.99	-27.56	81.12	-29.91	-37.99
Free Cash Flow	-81.98	-95.02	-66.77	-40.97	-38.01
Free Cash Flow Margin	-390.60%	-751.02%	-9995.81%	-	-
Free Cash Flow Per Share	-3.45	-4.05	-4.57	-80.53	-109.53

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).